表紙
市場調查報告書

酪氨酸蛋白激酶 CSK:開發中產品分析

Tyrosine Protein Kinase CSK - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 365776
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
酪氨酸蛋白激酶 CSK:開發中產品分析 Tyrosine Protein Kinase CSK - Pipeline Review, H1 2020
出版日期: 2020年06月30日內容資訊: 英文 96 Pages
簡介

本報告提供以酪氨酸蛋白激酶 CSK為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪氨酸蛋白激酶 CSK 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Advenchen Laboratories, LLC
  • Athenex, Inc.
  • Basilea Pharmaceutica AG
  • Pfizer Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2459TDB

Summary:

According to the recently published report 'Tyrosine Protein Kinase CSK - Pipeline Review, H1 2020'; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 12 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

The report 'Tyrosine Protein Kinase CSK - Pipeline Review, H1 2020' outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 2, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Hematological Disorders, Immunology, Infectious Disease, Respiratory and Toxicology which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), High-Grade Glioma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Arrhythmias, Asthma, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Blood Cancer, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Fallopian Tube Cancer, Fibrosarcoma, Follicular Lymphoma, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Leiomyosarcoma, Liposarcoma, Lung Adenocarcinoma, Lung Cancer, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Mild Cognitive Impairment, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Myocardial Infarction, Nasopharyngeal Cancer, Natural Killer Cell Lymphomas, Oligodendroglioma, Ovarian Cancer, Peritoneal Cancer, Polycythemia Vera, Prostate Cancer, Psoriasis, Pulmonary Arterial Hypertension, Radiation Injury, Renal Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, Systemic Mastocytosis, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Overview
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • Advenchen Laboratories LLC
  • Athenex Inc
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Pulmatrix Inc
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles
  • apatinib mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bosutinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dasatinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eCF-506 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Advenchen Laboratories LLC, H1 2020
  • Pipeline by Athenex Inc, H1 2020
  • Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Pipeline by Pfizer Inc, H1 2020
  • Pipeline by Pulmatrix Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020